Trial Profile

Phase I Dose-Escalation Extension Study to Determine the Safety and Tolerability of Intratumoural Injection(s) of EBC-46

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tigilanol tiglate (Primary)
Indications Head and neck cancer; Malignant melanoma; Skin cancer
Focus Adverse reactions
Sponsors QBiotics

Most Recent Events

19 Jul 2017 Status changed from recruiting to completed.
08 Sep 2016 Planned number of patients changed from 30 to 15.
19 Mar 2015 Planned initiation date changed from 22 Dec 2014 to 13 Mar 2015, as reported by Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com